Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if XLO is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
8 top institutions tracked
Last 13F trend: accumulating (heavy)
Unlock crowding heatmapUnlock filer discoverySentiment: unknown
No recent insider trades detected.
Red flags: 0
27 filers reported a long position in XLO for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | $6.4M | 664K | Unchanged |
| GILEAD SCIENCES, INC. | $6.2M | 650.4K | Unchanged |
| ORBIMED ADVISORS LLC | $5.7M | 592.3K | New |
| Frazier Life Sciences Management, L.P. | $4M | 422.5K | Unchanged |
| Stonepine Capital Management, LLC | $2.2M | 226K | +252.2% |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.7M | 178.5K | +44.4% |
| Sio Capital Management, LLC | $1.5M | 152.5K | Unchanged |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $1.1M | 111.5K | New |
| Merck & Co., Inc. | $1M | 106K | Unchanged |
| RENAISSANCE TECHNOLOGIES LLC | $614.6K | 64.2K | +29.4% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.